Sanofi reports data from Phase II demyelinating polyneuropathy trial
According to the latest data, riliprubart treatment showed encouraging efficacy and safety in trial subjects.
26 June 2024
26 June 2024
According to the latest data, riliprubart treatment showed encouraging efficacy and safety in trial subjects.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.